PDS Biotechnology (NASDAQ:PDSB) Receives “Buy” Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $21.00 price objective on the stock.

Several other equities analysts have also commented on the company. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. B. Riley lowered their price objective on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, June 12th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, PDS Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $14.25.

PDS Biotechnology Stock Performance

Shares of PDSB opened at $3.06 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The business’s fifty day moving average price is $3.38 and its 200 day moving average price is $3.52. The stock has a market capitalization of $112.24 million, a PE ratio of -2.25 and a beta of 1.88.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the business earned ($0.37) earnings per share. Equities research analysts forecast that PDS Biotechnology will post -1.3 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PDSB. Kathleen S. Wright Associates Inc. acquired a new position in PDS Biotechnology during the 1st quarter worth $28,000. Tempus Wealth Planning LLC acquired a new stake in PDS Biotechnology in the second quarter worth about $55,000. Ground Swell Capital LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in PDS Biotechnology during the 2nd quarter valued at about $115,000. Finally, Squarepoint Ops LLC acquired a new position in PDS Biotechnology during the 2nd quarter valued at about $120,000. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.